SITC Multiple Myeloma
Immunotherapy Guideline

The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of Multiple Myeloma in the Journal for ImmunoTherapy of Cancer on July 12, 2020.

SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

The Multiple Myeloma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations for FDA-approved immunotherapies for multiple myeloma, as well as discussion of promising emerging treatment modalities including chimeric antigen receptor T cell therapies and novel monoclonal antibody agents directed against B cell maturation antigen, and patient quality of life issues.

Published Guideline

Published July 12, 2020 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma""

READ GUIDELINE

Webinar Series

SITC is pleased to offer companion educational resources in support of the published Multiple Myeloma CPG. These activities feature faculty comprised of the guideline expert panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios.  The educational available features both webinars which are a longer-format recording that takes a deeper look at the guideline recommendations as well as mini-modules which are brief videos on a specific topic within the guideline content. Below is a list of the available educational resources for this CPG available free and on-demand.

• *Immunotherapy for the Treatment of Multiple Myeloma- SITC CPG Webinar
  • Leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma" during a live webinar.

• Practical Management Pearls for Immunotherapy for the Treatment of Multiple Myeloma- SITC CPG Webinar
  • This advanced webinar explains how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.

• Case Studies in Immunotherapy for the Treatment of Multiple Myeloma- SITC CPG Webinar
  • This high-level webinar will include case studies that illustrate execution of guideline recommendations, as well as discussion on difficult topics related to case management, as outlined in the Multiple Myeloma CPG.

• Antibody-Drug Conjugates
  • In this module, Dr. Jesus Berdeja, MD - Sarah Cannon Research Institute, Dr. Nina Shah, MD University of California - San Francisco, and Dr. Yi Lin, MD PhD, Mayo Clinic, describe the use of antibody-drug conjugates, specifically belantamab mafodotin, in multiple myeloma.  A particular focus is placed on the ocular toxicities of this agent and ways to manage patients on this therapy as a result.
• CAR T and Bispecifics
  • In this module, Dr. Yi Lin, MD PhD, Mayo Clinic, discusses novel approaches, such as CAR T therapies and bispecific agents for multiple myeloma.  A particular focus is on emerging trials of these agents, with a look to how they may impact clinical practice in the future.
• Monoclonal Antibodies
  • In this module, Dr. Jesus Berdeja, MD, Sarah Cannon Research Institute, describes the approved uses of anti-CD38 and anti-SLAMF7 antibodies in multiple myeloma. It also introduces emerging areas for the use of these agents, including their use in earlier lines of therapy and managing CD38-refractory disease.